ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc (MDP)

3,91
-0,05
(-1,26%)
Geschlossen 07 Juni 10:12PM

Medexus Pharmaceuticals Inc (MDP) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
3,91
( -1,26% )
Gebot
3,85
Fragen
3,92
Volumen
32.646
3,85 Tagesbereich 4,04
2,47 52-Wochen-Bereich 4,17
Marktkapitalisierung
Handelsende
3,96
Handelsbeginn
4,04
Letzte Trade
200
@
3.91
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
$ 51.230
Ausgegebene Aktien
31.834.683
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-331,04
Gewinn pro Aktie (EPS)
-0,01
Erlöse (LTM)
99,43M
Nettogewinn (LTM)
-272k

Über Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant... Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Website
Hauptsitz
Toronto, Canada
Gegründet
2026
Medexus Pharmaceuticals Inc is listed in the Healthcare sector of the Toronto Börse with ticker MDP. The last closing price for Medexus Pharmaceuticals was $3,96. Over the last year, Medexus Pharmaceuticals shares have traded in a share price range of $ 2,47 to $ 4,17.

Medexus Pharmaceuticals currently has 31.834.683 shares in issue. The market capitalisation of Medexus Pharmaceuticals is $124,47 million. Medexus Pharmaceuticals has a price to earnings ratio (PE ratio) of -331.04.

MDP Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.010.256410256413.94.053.79481203.93544479CS
40.010.256410256413.94.173.72427243.95275391CS
120.8728.61842105263.044.172.92531193.66989163CS
261.1843.22344322342.734.172.52488603.28345301CS
520.9933.9041095892.924.172.47463603.08598952CS
1562.68217.8861788621.235.551.12514532.74766345CS
260-3.47-47.01897018977.387.90.88442952.73141477CS

MDP - Frequently Asked Questions (FAQ)

What is the current Medexus Pharmaceuticals Inc share price?
The current share price of Medexus Pharmaceuticals Inc is $ 3,91
How many Medexus Pharmaceuticals Inc shares are in issue?
Medexus Pharmaceuticals Inc has 31.834.683 shares in issue
What is the market cap of Medexus Pharmaceuticals Inc?
The market capitalisation of Medexus Pharmaceuticals Inc is CAD 124,47M
What is the 1 year trading range for Medexus Pharmaceuticals Inc share price?
Medexus Pharmaceuticals Inc has traded in the range of $ 2,47 to $ 4,17 during the past year
What is the PE ratio of Medexus Pharmaceuticals Inc?
The price to earnings ratio of Medexus Pharmaceuticals Inc is -331,04
What is the cash to sales ratio of Medexus Pharmaceuticals Inc?
The cash to sales ratio of Medexus Pharmaceuticals Inc is 0,91
What is the registered address of Medexus Pharmaceuticals Inc?
The registered address for Medexus Pharmaceuticals Inc is 10 King Street East, Toronto, Ontario, M5C 1C3
What is the Medexus Pharmaceuticals Inc website address?
The website address for Medexus Pharmaceuticals Inc is www.medexus.com
Which industry sector does Medexus Pharmaceuticals Inc operate in?
Medexus Pharmaceuticals Inc operates in the Pharmaceuticals sector

MDP Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen